생리 식염수 시장 예측(-2032년) : 제품 유형, 포장 유형, 유통 채널, 용도, 최종 사용자, 지역별 분석

According to Stratistics MRC, the Global Physiological Saline Market is accounted for $5.70 billion in 2025 and is expected to reach $10.36 billion by 2032 growing at a CAGR of 8.9% during the forecast period. Physiological saline, or normal saline, is a sterile 0.9% sodium chloride solution that mirrors the salt concentration found in human blood and tissues. It is widely used in healthcare for intravenous therapy, cleaning wounds, eye washes, and as a carrier for drugs. Being isotonic, it preserves cellular integrity, aids hydration, and ensures electrolyte balance, making it essential for various clinical applications.

According to the 2024 Procedural Statistics Release, approximately 1,585,878 cosmetic surgeries were performed in 2024, representing a 1% increase compared to 2023, while reconstructive procedures rose by 2% during the same period, underscoring steady growth in surgical interventions.

Market Dynamics:

Driver:

Rising volume of surgical and medical procedures

The increasing frequency of surgical and medical interventions is significantly boosting the demand for physiological saline solutions. As chronic illnesses like diabetes, cardiovascular conditions, and cancer become more prevalent, hospitals are performing more procedures that require saline for hydration, irrigation, and drug dilution. Technological advancements in minimally invasive and robotic-assisted surgeries are further amplifying saline usage across operating rooms. Aging populations and improved diagnostic capabilities are contributing to higher hospitalization rates globally. Saline is also being integrated into personalized treatment regimens, especially in post-operative care and intravenous therapies. This surge in procedural volume is positioning physiological saline as a critical component in modern clinical workflows.

Restraint:

Supply chain vulnerabilities and shortages

Disruptions in the availability of medical-grade plastics and sterile packaging materials have impacted production timelines. Manufacturers are increasingly adopting predictive analytics and digital logistics platforms to manage inventory and mitigate delays. However, regional lockdowns, labor constraints, and transportation bottlenecks continue to strain distribution networks. Smaller producers often struggle with sourcing raw materials and maintaining regulatory compliance, slowing market responsiveness. Without robust contingency strategies, the industry risks inconsistent supply to hospitals and home care providers.

Opportunity:

Increasing Use in biopharmaceuticals and injectable drug delivery

Physiological saline is gaining traction as a carrier solution in biopharmaceutical formulations and injectable therapies. Its compatibility with biologics and stability in drug delivery systems make it ideal for intravenous and subcutaneous applications. The rise of monoclonal antibodies, vaccines, and biosimilars is driving demand for sterile saline in clinical trials and commercial production. Innovations in pre-filled syringes and auto-injectors are expanding saline's role in patient-centric drug administration. Regulatory support for single-dose packaging and aseptic processing is encouraging broader adoption. This trend opens new avenues for saline manufacturers to collaborate with pharma companies and invest in advanced filling technologies.

Threat:

Environmental concerns over plastic packaging

The widespread use of plastic containers for saline solutions is raising environmental sustainability concerns. Disposal of single-use saline bags and bottles contributes to medical waste, prompting scrutiny from regulators and environmental groups. Manufacturers are exploring biodegradable polymers and recyclable packaging to reduce ecological impact. Emerging technologies like lightweight flexible pouches and reusable delivery systems are gaining attention. Hospitals are also adopting green procurement policies, favoring suppliers with eco-friendly credentials. If sustainability measures are not prioritized, the market may face regulatory pressure and reputational risks.

Covid-19 Impact:

The COVID-19 pandemic disrupted the physiological saline supply chain, delaying elective procedures and straining hospital resources. Lockdowns led to manufacturing slowdowns and logistical challenges, resulting in shortages of essential saline products. However, the crisis accelerated digital transformation in healthcare, including remote monitoring and telemedicine, which indirectly increased demand for home-based saline therapies. Emergency approvals and fast-track regulatory pathways helped maintain supply continuity during peak demand. Post-pandemic strategies now emphasize decentralized production, automation, and resilient sourcing models.

The normal saline segment is expected to be the largest during the forecast period

The normal saline segment is expected to account for the largest market share during the forecast period, due to its broad clinical utility. It is widely used for intravenous hydration, wound irrigation, and as a diluent for injectable drugs. Hospitals and clinics rely on it for routine procedures, emergency care, and post-operative recovery. Technological advancements in sterile filling and packaging have improved shelf life and safety. The rise in outpatient treatments and home infusions is further boosting demand for ready-to-use saline formats. As healthcare systems prioritize cost-effective and versatile solutions, normal saline remains the cornerstone of fluid therapy.

The home healthcare segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the home healthcare segment is predicted to witness the highest growth rate. Increasing patient preference for at-home treatments, especially for chronic conditions, is driving demand for portable saline delivery systems. Innovations in wearable infusion pumps and pre-filled saline kits are enhancing convenience and compliance. Telehealth integration allows remote monitoring of saline administration, improving safety and outcomes. Reimbursement support and aging populations are further propelling this segment's expansion. As care shifts from hospitals to homes, physiological saline is becoming essential in decentralized treatment models.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by rapid healthcare infrastructure development. Countries like China, India, and Japan are investing heavily in hospital expansion and medical device manufacturing. Government initiatives promoting local production and import substitution are strengthening regional supply chains. Adoption of robotic surgeries and AI-based diagnostics is increasing saline usage in advanced procedures. Strategic collaborations between global players and local firms are enhancing technology transfer and market penetration. The region's large patient base and rising surgical volumes make it a key growth engine.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fueled by innovation and strong R&D investment. The U.S. and Canada are leading in smart infusion systems, automated compounding, and AI-driven patient monitoring. Regulatory bodies are streamlining approvals for next-gen saline packaging and delivery formats. Hospitals are adopting IoT-enabled inventory systems to optimize saline usage and reduce waste. Favorable reimbursement policies and high adoption of home-based care are accelerating market growth. As precision medicine and personalized therapies gain momentum, North America continues to set the benchmark for saline innovation.

Key players in the market

Some of the key players in Physiological Saline Market include Baxter International Inc., B. Braun Melsungen AG, Fresenius Kabi, ICU Medical, Inc., Pfizer Inc., Otsuka Pharmaceutical Co., Ltd., Grifols, S.A., Terumo Corporation, Sichuan Kelun Pharmaceutical, SSY Group Ltd., Cisen Pharmaceutical Co., Ltd., Nipro Corporation, Amsino International, Inc., Medline Industries, L., and Double-Crane Pharmaceutical Co., Ltd.

Key Developments:

In September 2025, Baxter International Inc. launched the Welch Allyn Connex 360 Vital Signs Monitor, its next generation patient monitoring device. As the latest innovation in Baxter's connected monitoring portfolio, Connex 360 offers an advanced connectivity and security platform, customizable configurations based on a hospital's clinical routines, and upgrade capabilities that set the stage for future functionality and enhancements.

In September 2025, B. Braun SE announced the full acquisition of True Digital Surgery (TDS), a company based in Goleta, California, specializing in digital robotic-assisted 3D surgical microscopy. This acquisition highlights B. Braun's commitment to investing in the future of digital microsurgery and to expanding its market share in this growing segment.

Product Types Covered:

• Normal Saline
• Hypertonic Saline
• Hypotonic Saline
• Buffered Saline
• Other Product Types

Packaging Types Covered:

• Plastic Bottles
• Glass Bottles
• Pouches/Bags
• Pre-filled Syringes

Distribution Channels Covered:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Applications Covered:

• Intravenous Therapy
• Dialysis
• Wound Care & Irrigation
• Laboratory Use
• Ophthalmology
• Other Applications

End Users Covered:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Research & Academic Institutes
• Home Healthcare
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Physiological Saline Market, By Product Type

• 5.1 Introduction
• 5.2 Normal Saline
• 5.3 Hypertonic Saline
• 5.4 Hypotonic Saline
• 5.5 Buffered Saline
• 5.6 Other Product Types

6 Global Physiological Saline Market, By Packaging Type

• 6.1 Introduction
• 6.2 Plastic Bottles
• 6.3 Glass Bottles
• 6.4 Pouches/Bags
• 6.5 Pre-filled Syringes

7 Global Physiological Saline Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Hospital Pharmacies
• 7.3 Online Pharmacies
• 7.4 Retail Pharmacies

8 Global Physiological Saline Market, By Application

• 8.1 Introduction
• 8.2 Intravenous Therapy
• 8.3 Dialysis
• 8.4 Wound Care & Irrigation
• 8.5 Laboratory Use
• 8.6 Ophthalmology
• 8.7 Other Applications

9 Global Physiological Saline Market, By End User

• 9.1 Introduction
• 9.2 Hospitals & Clinics
• 9.3 Ambulatory Surgical Centers
• 9.4 Research & Academic Institutes
• 9.5 Home Healthcare
• 9.6 Other End Users

10 Global Physiological Saline Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Baxter International Inc.
• 12.2 B. Braun Melsungen AG
• 12.3 Fresenius Kabi
• 12.4 ICU Medical, Inc.
• 12.5 Pfizer Inc.
• 12.6 Otsuka Pharmaceutical Co., Ltd.
• 12.7 Grifols, S.A.
• 12.8 Terumo Corporation
• 12.9 Sichuan Kelun Pharmaceutical
• 12.10 SSY Group Ltd.
• 12.11 Cisen Pharmaceutical Co., Ltd.
• 12.12 Nipro Corporation
• 12.13 Amsino International, Inc.
• 12.14 Medline Industries, LP.
• 12.15 Double-Crane Pharmaceutical Co., Ltd.